Novartis pushing Kisqali into younger patients to gain edge

Topline results from a Phase 3 study in younger women with breast cancer could give the CDK 4/6 inhibitor an advantage over competitors. 

By Lisa LaMotta • Nov. 8, 2017

FDA lifts clinical hold on Cellectis CAR-T

Cellectis agreed to several changes to two Phase 1 trials testing its allogeneic CAR-T candidate, both of which had been halted after a patient death in late August.

By Ned Pagliarulo • Nov. 7, 2017

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Could pain data give Lilly's baricitinib back its edge?

After its put-down from the FDA earlier this year, pain data could boost the profile of the drugmaker's arthritis hopeful.

By Suzanne Elvidge • Nov. 6, 2017

Reata buoyed by positive data for kidney disease drug

Results from a mid-stage study could boost confidence in Reata's treatment for patients with an inherited form of CKD.

By Suzanne Elvidge • Nov. 6, 2017

Partnering for drug discovery success

Kathryn Chapman, Executive Manager of The Milner Therapeutics Institute, and Charles McOsker, Senior VP of Technical Operations at BioMotiv, talk about how alliances with CRO/CMOs are becoming an integral part of R&D approaches as they contribute to building key scientific evidence for drug development programs for clinical success.

Nov. 3, 2017

Alnylam outshines Ionis with RNAi drug

Patisiran reverses impairment and improves quality of life in patients with a rare disease, paving the way for potential approval of the first RNAi treatment. 

By Suzanne Elvidge • Nov. 3, 2017

Aisling Capital raises $280M in latest fund

The New York-based life sciences investment firm looks to help clinical stage ventures bring treatments to market.

By Suzanne Elvidge • Nov. 3, 2017

Prescribed Reading: Cancer market facing several shake-ups

Merck pulled a Keytruda application in Europe, and AstraZeneca got a key approval for Calquence — decisions that could have dramatic impacts on different areas of the oncology space. 

By Lisa LaMotta • Nov. 3, 2017

Proving flexibility in oncology early clinical development

By remaining attuned to the dynamic nature of oncology drug development, time, cost and risk can all be efficiently minimized while successfully managing safety and ethical considerations during the early clinical development journey.

Nov. 2, 2017

Third flop dims hopes for AstraZeneca's asthma drug

The British pharma adds two more late-stage failures to an earlier setback for tralokinumab. 

By Lisa LaMotta • Nov. 1, 2017

Bluebird marks progress on Lentiglobin gene therapy

Manufacturing changes made last fall appear to have improved the biotech's treatment for sickle cell disease. But will the new data be enough to boost investor confidence? 

By Ned Pagliarulo • Nov. 1, 2017

AstraZeneca looks to build edge in early-stage lung cancer

Following a now well-worn path, AstraZeneca will pair its PD-L1 inhibitor Imfinzi with Incyte's epacadostat in hopes of building on strong data from its PACIFIC study. 

By Ned Pagliarulo • Oct. 31, 2017

Pharma's betting big on China, but R&D boom still to come

Despite a major regulatory shift, China's ascendency as the next global hub of drug R&D may still be a ways off.

By Ned Pagliarulo • Oct. 30, 2017

Late-stage ozanimod data brings Celgene closer to filing

After a challenging third quarter, RADIANCE and SUNBEAM Phase 3 MS results could shine light through Celgene's clouds.

By Suzanne Elvidge • Oct. 30, 2017

Swiss biotech GeNeuro jumps on redeeming MS analysis

A new post-hoc analysis in multiple sclerosis patients taking GNbAC1 showed new potential, boosting the drug's prospects. 

By Lisa LaMotta • Oct. 30, 2017

Prescribed Reading: Disappointing quarters all around

With some exceptions, third quarter reports so far have largely been a letdown for the sector, lowering expectations as investors turn toward 2018. 

By Lisa LaMotta • Oct. 27, 2017

AbbVie's anti-inflammatories key to growth

Humira sales increased to $4.7 billion during the third quarter, and late-stage drugs upadacitinib and risankizumab are poised to offer strong returns in the coming years.

By Jacob Bell • Oct. 27, 2017

Vertex grows CF franchise as combos move forward

The outlook for Vertex is bright, as positive data from experimental combination treatments could eventually position the biotech to reach 90% of cystic fibrosis patients.

By Ned Pagliarulo • Oct. 26, 2017

Mixed results in NASH for Gilead

While the higher dose showed a clinical effect, GS-0976 didn't hit the mark at its lowest dose, and the study missed its additional endpoints.

By Suzanne Elvidge • Oct. 25, 2017

Global Blood abandons IPF indication after multiple trial letdowns

Focus now turns to the Phase 3 HOPE study, which is testing oral GBT440 in patients with sickle cell disease.

By Jacob Bell • Oct. 23, 2017

Immuno-oncology: Am I choosing the right biomarker?

Learn how to choose the right biomarker for your immuno-oncology trial in this Q&A.

By Mario Rocci Jr., Senior Vice President at ICON Laboratories • Oct. 23, 2017

DBV forges ahead with peanut allergy treatment despite study miss

Trial results, which fell just shy of goal, won't stop DBV from filing its treatment for U.S. approval. 

By Suzanne Elvidge • Oct. 22, 2017

UniQure shares jump on trial plans for revamped hemophilia gene therapy

Shaking off recent setbacks, the Dutch biotech will advance a reworked version of its hemophilia B candidate into a pivotal study next year.

By Suzanne Elvidge • Oct. 20, 2017

Prescribed Reading: Blockbuster potential thwarted; generics consolidate

The past week saw multiple companies discontinue development of potential blockbusters, while a tightening generics market prompted a new merger.

By Lisa LaMotta • Oct. 20, 2017

Celgene calls it quits on expensive Crohn's drug

The big biotech is discontinuing development of a potential blockbuster, putting pressure on its pipeline product ozanimod to outperform.

By Jacob Bell • Oct. 20, 2017